BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

总部位于马萨诸塞州剑桥的Sage Therapeutics, Inc.宣布，其首席医疗官Laura Gault医学博士将于2025年3月21日离职。该生物制药公司专注于开发治疗中枢神经系统疾病的药物，目前维持着现金多于债务的强健资产负债表。公司周一确认，Gault博士的离职并非由于任何内部分歧，而是为了寻求新的发展机会。

马萨诸塞州剑桥市 - 市值4.49亿美元、专注于脑健康治疗的生物制药公司Sage Therapeutics, Inc. (NASDAQ: SAGE )今日宣布，其首席医疗官Laura Gault博士将离职寻求新的发展机会。她的离职将于2025年3月21日生效。Gault博士自2022年11月加入公司以来，一直负责监督公司的产品管线开发。根据 InvestingPro ...

Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since rejecting Biogen’s unsolicited acquisition offer. Sage Therapeutics Inc.

Sage Therapeutics and partner Biogen equally shares profits and losses for the commercialization of Zurzuvae in the United States. In ex-U.S. markets, Biogen records product sales (excluding Japan ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $1.3 million in the fourth quarter of 2024 compared to $8.3 million in ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc ... Collaboration revenues represent 50% of the net revenues recorded when Biogen ships ZURZUVAE to the distributors. For the year ended December ...